Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||-1.85%||731.86||2.6%||$754.70m|
|GILD||Gilead Sciences, Inc.||-0.76%||64.95||1.0%||$550.05m|
|VRTX||Vertex Pharmaceuticals, Inc.||-1.12%||298.63||1.9%||$429.92m|
|SNSS||Sunesis Pharmaceuticals, Inc.||-1.47%||4.02||0.7%||$281.01m|
|SAVA||Cassava Sciences, Inc.||3.37%||42.35||0.0%||$189.68m|
|BMRN||BioMarin Pharmaceutical, Inc.||2.18%||91.48||4.2%||$95.92m|
|PRTA||Prothena Corp. Plc||0.79%||58.57||13.8%||$79.21m|
|SNTI||Senti Biosciences, Inc.||23.49%||6.52||0.0%||$78.99m|
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.